CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We maintain WN at Buy and our target at CAD107, based on our unchanged multiple of 19x our projected FY 27 EPS. We keep our FY 26 EPS estimate at CAD5.10 and FY 27 at CAD5.62. Our rating remains grounded in continued same-store sales (SSS) growth and its best-in-class value offering to the market in a time of affordability issues. WN is reaping the benefits of a stickier inflationary period and plans for nearly half of new stores opened in 2026 to be No Frills or Maxi logos. The company reported Q1 revenue of CAD14,639M, up 4.2% from the prior year. Adjusted net earnings rose 2.9% to CAD349M, while adjusted diluted EPS increased 5.8% to CAD0.91. Loblaw generated revenue of CAD14,484M, up 4.2%, with food retail same-store sales growth of 2.4% and drug retail same-store sales growth of 4.1%. Food sales increased on higher traffic and basket size, with internal food inflation below the 4.4% Consumer Price Index. The discount theme continues to grow as energy ricing remains elevated, stretching the consumer.